Datapoint: Eylea Scores Pediatric Retinopathy Nod

The FDA last week approved Regeneron Pharmaceuticals’ Eylea for the treatment of retinopathy of prematurity, one of the most common causes of childhood blindness, in preterm infants. The blockbuster injectable is now the only therapy approved in this space. Eylea, a VEGF inhibitor, was first approved in 2011 for the treatment of macular degeneration, an indication for which it holds covered or better status for 95% of all insured lives under the medical benefit. About 68% of insured lives have covered access to Eylea with utilization management restrictions, such as prior authorization and/or step therapy, applied.

SOURCE: MMIT Analytics, as of 2/13/23

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 20

Datapoint: Ipsen’s Latest Accelerated Approval Will Challenge Intercept’s Ocaliva

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 18

Datapoint: Texas Won’t Halt Latest Medicaid Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 17

Datapoint: Oscar Plans to Double Enrollment by 2027

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today